EPAS1 and somatostatinoma: This could be of importance in the clinical surveillance and management of patients presenting with sporadic instances of polycythemia linked to novel HIF2α mutations as the further risk of PPGL and somatostatinoma, which occur decades later than the onset of polycythemia in Class 1 disease4, could be theoretically predicted.